How to buy Atea Pharmaceuticals (AVIR) shares in the UK

Learn how to easily invest in Atea Pharmaceuticals shares.

Atea Pharmaceuticals Inc (AVIR) is a leading biotechnology business based in the US. In the week up to 22 November Atea Pharmaceuticals shares plunged 32.48% to a closing position of $7.67. Over the last 12 months, Atea Pharmaceuticals's share price has fallen by 20.00% from $29.25. Atea Pharmaceuticals is listed on the NASDAQ and employs 56 staff. All prices are listed in US Dollars.

How to buy shares in Atea Pharmaceuticals

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AVIR in this case.
  5. Research Atea Pharmaceuticals shares. The platform should provide the latest information available.
  6. Buy your Atea Pharmaceuticals shares. It's that simple.
The whole process can take as little as 15 minutes.

Atea Pharmaceuticals share price (NASDAQ:AVIR)

Use our graph to track the performance of AVIR stocks over time.

Atea Pharmaceuticals shares at a glance

Information last updated 2021-06-16.
Previous close$23.58
Change %-0.7634%
Information last updated 2021-11-30.
52-week range$7.37 - $94.1737
50-day moving average$22.1472
200-day moving average$34.1358
Wall St. target price$13.67
PE ratio25.1282
Dividend yieldN/A (0%)
Earnings per share (TTM)$0.312
eToro Free Stocks

Invest in Atea Pharmaceuticals shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 50x Atea Pharmaceuticals shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $50 £4.41
£886.83 total
Capital at risk
Fineco logo £0 No minimum £8.82
£891.24 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.88
£883.30 total
Capital at risk
Stake logo £0 £50 £4.41
£886.83 total
Capital at risk
IG Share Dealing logo £0 £250 £11.99
£894.41 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £20.77
£903.19 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £21.23
£903.64 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £20.53
£902.94 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Atea Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Atea Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Atea Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Atea Pharmaceuticals shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.


Atea Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $37.9 million (£0.0 million).

The EBITDA is a measure of a Atea Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.


Revenue TTM $207.8 million
Operating margin TTM 18.21%
Gross profit TTM $10.6 million
Return on assets TTM 4.96%
Return on equity TTM 7.26%
Profit margin 11.89%
Book value $7.001
Market capitalisation $651.5 million

TTM: trailing 12 months

Atea Pharmaceuticals share dividends

We're not expecting Atea Pharmaceuticals to pay a dividend over the next 12 months. Typically it's companies that have been around for longer that pay dividends (Atea Pharmaceuticals had its IPO on 29 October 2020). However, you can browse other dividend-paying shares in our guide.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site